TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese male~* Have a legal representative who provides written informed consent for the trial on the participant's behalf~* Have a legal representative who is able to read, understand, and complete the vaccine report card~* Has not yet had coitarche and does not plan on becoming sexually active from Day 1 through Month 7 of the study~* Other inclusion criteria will be discussed with the investigator during screening~Exclusion Criteria:~* Currently enrolled in clinical studies of investigational agents~* History of known prior vaccination with an HPV vaccine or plans to receive one outside the study~* History of severe allergic reaction that required medical intervention~* Allergic to any vaccine component, including aluminum, yeast, or BENZONASE™~* Received immune globulin or blood-derived products in the past 6 months or plans to receive any before Month 7 of the study~* History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition~* Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids~* Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections~* Ongoing alcohol or drug abuse within the past 12 months~* History of genital warts or a positive test for HPV

- Gender: MALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet the following inclusion criteria to be eligible for the study.~* Subject can provide written informed consent and is willing to comply with study procedures.~* Subject is at least 18 years of age.~* Subject has focal epilepsy with classifiable seizures according to the International Classification of Epileptic Seizures, 1981.11~* Subject is deemed to be an appropriate candidate for LCM adjunctive therapy.~* Subject has been maintained on a stable dose of 1 or 2 marketed AEDs for at least 4 weeks.~Exclusion Criteria:~Subjects must meet the following exclusion criteria to be eligible for the study.~* Subject has a history of a moderate or severe sleep apnea (apnea-hypopnea index \[AHI\] \> 15), severe insomnia (habitual sleep duration \< 4 hours) or narcolepsy.~* Subject has a score on the Sleep Apnea Scale of the Sleep Disorders Questionnaire (SA/SDQ) at screening of 32 or higher (female) and 36 or higher (male).~* Subject is currently participating or has participated within the last 2 months in a trial of an investigational drug or experimental device.~* Subject has seizures or seizures clusters that are not quantifiable.~* Subject has 6 or more seizures (excluding auras) in the 2-week Baseline Phase.~* Subject has a medical condition that could reasonably be expected to interfere with drug absorption, distribution, metabolism or excretion.~* Subject has any medical or psychiatric condition, which in the opinion of the investigator, could jeopardize the subject's health or would compromise the - Subject has a history of alcohol or drug abuse within the previous 2 years.~* Subject has an acute or sub-acutely progressive central nervous system disease.~* Subject is pregnant, breastfeeding or of childbearing age and not surgically sterile or practicing an acceptable form of contraception (barrier contraception, surgically sterilized, IUD, abstinence) for the duration of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks~* Subjects who meets the indication of EutropinPen inj.~Exclusion Criteria:~* Subjects who has diseases below on screening visit~  * Diabetes~ * Malignant tumor~ * Epiphyseal closure~ * Chronic kidney disease (recieved kidney transplantation)~ * Acute respitory failure

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Eutropin pen inj. (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese Patients With Type 2 Diabetes Mellitus, Who Have Inadequate Glycemic Control On Diet/Exercise Therapy And Voglibose Monotherapy~Exclusion Criteria:~* Patients Have A History Of Type 1 Diabetes Mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin/Sitagliptin (Type: EXPERIMENTAL): None
- Placebo/Sitagliptin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of biopsy-proven celiac disease~* Adherence to a gluten-free diet~* TG2 antibody negative~* Signed informed consent~Exclusion Criteria:~* Active dermatitis herpetiformis~* History of IgE-mediated reactions to gluten~* Use of specific medications 6 months prior to entry~* History of alcohol abuse or illicit drug use~* Current untreated or GI disease~* Positive pregnancy test~* Received any experimental drug within 14 days of randomization~* Uncontrolled chronic disease or condition~* Uncontrolled complications of celiac disease~* Any medical condition which could adversely affect study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALV003 (Type: EXPERIMENTAL): ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
- Placebo (Type: PLACEBO_COMPARATOR): Excipients for ALV003 absent the experimental compounds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients are 20 years of age or older~* patients had chronic pain for more than 3 months and average pain score for last 3 days is not less than 4 (NRS)~* neuropathic pain caused by the spinal stenosis (radiating pain, motor or sensory change~* positive MRI finding or radiculopathy was confirmed by the EMG/NCS or not less than 12 points in the S-LANSS score assessment~* patients who can make out the questionnaire~* patients have agreed with the informed consent~Exclusion Criteria:~* patients who have experience with gabapentin, pregabalin, fentanyl matrix, long-acting strong opioid (CR oxycodone, SR morphine)~* patients who have other causes of neuropathy such as hypothyroidism, Vit B12 deficiency, connective tissue disease, etc.~* patients who have other disease which causes more pain compared with neuropathic pain~* patients with a history of drug or alcohol abuse~* patients who are pregnant or have the possibility of pregnancy~* patients who are unable to use a transdermal system due to skin disease~* patients with a serious mental disease~* patients with a history of hypersensitivity to opioid analgesics~* patients with a chronic pulmonary disease or respiratory depression~* patients combined with industrial accidents or traffic accidents~* at investigator's discretion, any condition where a subject cannot take part in the clinical study on the ground of warning, cautions, and prohibition in study investigator's brochure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Transdermal fentany matrix (Type: EXPERIMENTAL): Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
- gabapentin (Type: ACTIVE_COMPARATOR): Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old (inclusive)~* Diagnosed with PNH (white blood cell (WBC) clone \>10%)~* Lactose dehydrogenase (LD) ≥2 times the upper limit of normal~* Screening Ferritin ≥ normal and Total Iron Binding Capacity (TIBC) \< LLN based on central lab reference ranges. If a subject is receiving iron supplements at screening, the investigator must ensure that his/her dose has been stable for 8 weeks prior to enrolment and must be maintained throughout the study~* Last transfusion within 12 months prior to screening~* Platelet count of \>30,000/mm3 at the screening visit~* Absolute neutrophil count \>500/ mm3 at the screening visit~* Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study~* Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study~* Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits~* Willing and able to give informed consent~Exclusion Criteria:~* Prior eculizumab (Soliris®) treatment~* Active bacterial infection~* Hereditary complement deficiency~* History of bone marrow transplantation~* Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin~* Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days~* Evidence of QTcF prolongation defined as \>450 ms for males and \>470 ms for females at screening~* Breast-feeding women~* History of meningococcal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Cohort 1 (Type: EXPERIMENTAL): 270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364\*

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Each participant must be willing and able to provide written informed consent for the study.~* Each participant must be American Society of Anesthesiologists (ASA) class I, II or III.~* Each participant must be scheduled for elective laparoscopic surgery (this includes robotic laparoscopic surgery).~* Expected surgical duration of 60 min or longer~Exclusion Criteria:~* Inability to give informed oral or written consent~* Known or suspected neuromuscular disorders impairing neuromuscular function;~* True allergies as defined as hypotension, bronchospasm, or anaphylaxis to muscle relaxants, anesthetics or opioids~* A history (patient or family) of malignant hyperthermia~* A contraindication for neostigmine administration~* Renal insufficiency, as defined by serum creatinine levels at 2.5 fold the normal level~* Body mass index \>40 kg/m\^2~* Significant respiratory disease.~* Planned postoperative mechanical ventilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep to Moderate NMB (Type: OTHER): This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
- Moderate to Deep NMB (Type: OTHER): This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Patients with Philadelphia-Positive (Ph+) (or BCR/ABL+) accelerated phase chronic myeloid leukemia, Ph+ (or BCR/ABL+) blast phase chronic myeloid leukemia, or Ph+ (or BCR/ABL+) acute lymphoblastic leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate~* Men and women, 18 years of age or older~* Adequate hepatic function~* Adequate renal function~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy~* Uncontrolled or significant cardiovascular disease~* Medications that increase bleeding risk~* Medications that change heart rhythms~* Dementia or altered mental status that would prohibit the understanding or rendering of informed consent~* History of significant bleeding disorder unrelated to CML~* Concurrent incurable malignancy other than CML~* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy~* Prior therapy with BMS-35425~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dasatinib Twice a Day (BID) (Type: EXPERIMENTAL): 70 mg dasatinib twice a day (BID)
- dasatinib Once a Day (QD) (Type: EXPERIMENTAL): 140 mg dasatinib once a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 years of age or older~* Histologically confirmed HER2-positive metastatic breast cancer~* Trastuzumab-resistance~* Measurable disease, according to RECIST guidelines~* ECOG performance status less than or equal to 1~* Life expectancy greater than 3 months~* No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor~* At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus~* Left ventricular ejection greater than or equal to 50%~* Adequate cardiovascular function~* Adequate hematological, hepatic, and renal function~* Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL~* Negative pregnancy test within 7 days prior to first dose of study drug and must use an approved contraceptive method from screening to 30 days after the last dose of study drug~* Availability and patient consent to obtain archival tissue samples~* Signed informed consent~Exclusion Criteria:~* Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry~* Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration~* Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab~* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest~* Known allergy to macrolide antibiotics~* Pregnant or breast-feeding~* Know history of HIV~* Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months~* Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin~* Active infection requiring prescription intervention~* Newly diagnosed or poorly controlled Type 1 or 2 diabetes~* Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug~* Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.~* Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Steroid-refractory GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of graft-versus-host disease established based on tissue biopsy~* Steroid-refractory acute or chronic graft-versus-host disease according to EBMT/ELN criteria (T. Ruutu et al, 2014)~* Age 1 to 70 years~* Karnofsky index \>30%.~* Ability for oral drug intake~* Life expectancy \> 1 month~* Signed informed consent~Exclusion Criteria:~* Severe organ dysfunction: AST or ALT \>5 upper normal limits (excluding cases related to liver GVHD), creatinine \>2 upper normal limits~* Requirement for vasopressor support at the time of enrollment~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Pregnancy~* Somatic or psychiatric disorder making the patient (or legal guardian) unable to sign informed consent

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib treatment (Type: EXPERIMENTAL): Ruxolitinib 10 mg bid for adults and children with body weight \> 40 kg, 0.15 mg/kg bid for children with body weight \< 40 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete